| 发明名称 | Combined therapy for cystic fibrosis | ||
| 摘要 | There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ΔF508-CFTR mutation, and pharmaceutical compositions thereof. | ||
| 申请公布号 | US9132123(B2) | 申请公布日期 | 2015.09.15 |
| 申请号 | US201313895741 | 申请日期 | 2013.05.16 |
| 申请人 | I.E.R.F.C. European Institute For Cystic Fibrosis Research | 发明人 | Maiuri Luigi;Raia Valeria;Borella Fabio;Kroemer Guido |
| 分类号 | A61K31/47;A61K31/145;A61K31/37;A61K31/192;A61K31/7034;A61K31/05;A61K31/047;A61K31/357;A61K31/13;A61K31/198;A61K45/06;A61K31/366 | 主分类号 | A61K31/47 |
| 代理机构 | Silvia Salvadori, P.C. | 代理人 | Silvia Salvadori, P.C. |
| 主权项 | 1. A method of treating a cystic fibrosis in patients carrying ΔF508-CFTR mutation and positive for cystic fibrosis, said method comprising administering to said patients a combination of a) a tissue transglutaminase TG2 inhibitor and b) a channel activator (potentiator) of cystic fibrosis transmembrane conductance regulator (CFTR) and treating said cystic fibrosis. | ||
| 地址 | Milan IT | ||